LUXEMBOURG, December 15, 2010 /PRNewswire/ -- Creabilis SA, a clinical
stage European biotechnology company addressing unmet medical needs in
dermatology, today announced positive results in the Phase IIa study of its
lead product CT327 in atopic dermatitis.
CT327 is a novel topically appli